NPM1 and acute myeloid leukemia: To focus on AML with unmet prognostic and therapeutic needs, we excluded from our cohort AML cases of the favorable ELN prognostic group (t(8;21), inv(16), bi-allelic CEBPA, and NPM1 without FLT3-ITD mutations) [7].